MedTrace Logo

A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants

NCT05460455 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-01-23

No results posted yet for this study

Summary

The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following multiple-dose.

Conditions

  • Healthy

Interventions

DRUG

Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo

HB0034 and Placebo

Sponsors & Collaborators

  • Shanghai Huaota Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Christian Schwabe · NZCR OpCo limited AKL

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-13
Primary Completion
2023-06-09
Completion
2023-12-08

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05460455 on ClinicalTrials.gov